FDA Expands Use of Zoryve to Include Young Children With Plaque Psoriasis

TUESDAY, July 14, 2026 (HealthDay News) -- The U.S. Food and Drug Administration has approved an expanded indication for Zoryve (roflumilast) cream 0.3 percent for the topical treatment of plaque psoriasis in patients ages 2 years and older.Zoryve is a once-daily, steroid-free topical cream that is suitable for use anywhere on the body with no limitations on duration of use.The approval is based on data from a four-week Maximal Usage Systemic Exposure study evaluating Zoryve cream 0.3 percent in children ages 2 to 5 years with plaque psoriasis involving at least 2 percent of body surface area. Both the open-label study, which assessed pharmacokinetics, safety, tolerability, and exploratory efficacy in children, and supportive long-term safety data derived from an open-label extension study for up to 24 weeks of treatment showed safety and efficacy profiles that were generally consistent with those observed in the DERMIS-1 and DERMIS-2 pivotal phase 3 trials in adolescents and adults."Young children with plaque psoriasis face unique challenges, including disease involvement on sensitive skin, such as the face and skin folds," Lisa Swanson, M.D., a clinical trial investigator, said in a statement. "Although topical steroids are commonly used to treat pediatric plaque psoriasis, they are not recommended on sensitive areas or for long-term, continuous use."The expanded approval of Zoryve was granted to Arcutis Biotherapeutics.More Information.Sign up for our weekly HealthDay newsletter

FDA Expands Use of Zoryve to Include Young Children With Plaque Psoriasis

Related Stories

FDA Expands Use of First Sickle Cell Disease Gene Therapy for Children as Young as 2 Years

E. Coli Outbreak Prompts Recall Of Frozen Blueberries At Publix

Ultra-Processed Foods Linked to Brain Differences in Young Children

FDA Approves Tzield for Children With New Stage 3 Type 1 Diabetes